Videos

At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.

At the 2023 World Congress on Gastrointestinal Cancers, Monica Niger, MD, discusses the clinical relevance and actionability of BRAF alterations among patients with advanced biliary tract cancers.

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.

Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.

Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.

Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.

At the 2023 World Congress on Gastrointestinal Cancers, Alfonso De Stefano, MD, PhD presented results of the IMPROVE study on intermittent or continuous panitumumab plus FOLFIRI for the first-line treatment of patients with RAS/BRAF wild-type...

At the 2023 World Congress on Gastrointestinal Cancers, Eric Lander, MD, presents genomic clustering data suggesting that early-onset colorectal cancer may be caused by unique mutagenic processes compared to average-onset colorectal cancer.

At the 2023 World Congress on Gastrointestinal Cancers, Antonella Cammarota, MD, presented results from a study relating prior chemotherapy administration with heterogeneity of CLDN18.2 among patients with resectable gastroesophageal cancers.

Ajai Chari, MD, discusses the significance of the accelerated approval of talquetamab for the treatment of patients with R/R multiple myeloma, as well as offers advice for practicing oncologists regarding using this therapy.